放射性标记GRPR拮抗剂BAY86-7548用于新诊断前列腺癌正电子发射断层扫描/计算机断层扫描成像的前瞻性研究
这项前瞻性研究纳入16例活检证实的前列腺癌患者,在新诊断后行68Ga-RM2 PET/CT、多参数MRI及二者融合图像评估,以全mount病理为参考标准。结果显示68Ga-RM2 PET/CT与mpMRI的灵敏度、特异度和准确度无显著差异,融合图像使灵敏度和准确度最大化(分别为85.2%和83.9%),特异度平均为81.3%。作者认为68Ga-RM2 PET/CT对原发前列腺癌检测和定位有前景,可补充mpMRI。
要点
- 68Ga-RM2 PET/CT与mpMRI对前列腺癌灶检测的灵敏度、特异度和准确度无显著差异。
- 融合68Ga-RM2 PET/CT与mpMRI使灵敏度和准确度最大化(分别为85.2%和83.9%)。
- GRPR与PSMA表达不相关(r=0.3882),提示二者靶向PET成像可能互补。
核心结论
- 68Ga-RM2 PET/CT对原发前列腺癌的检测和定位有前景,可补充mpMRI。
- GRPR表达似乎独立于PSMA表达,提示GRPR靶向和PSMA靶向PET成像可能互补。
研究设计与样本
- 前瞻性研究纳入16例活检证实的前列腺癌患者(2例低危、8例中危、6例高危)。
- 在mpMRI后4周内、根治性前列腺切除加扩大双侧盆腔淋巴结清扫前2周内行68Ga-RM2 PET/CT。
- 由盲法专科医生采用5点Likert量表评估前列腺12个解剖区域,评分4或5分视为阳性。
- 以全mount step-section病理为参考标准。
- 对肿瘤石蜡切片行免疫组化分析GRPR和PSMA表达。
主要发现
- 共分析192个区域,其中128个含癌。
- 68Ga-RM2 PET/CT与mpMRI的灵敏度、特异度和准确度无显著差异。
- 融合图像的灵敏度和准确度最大化(分别为85.2%和83.9%),特异度平均为81.3%。
- ROC曲线下面积:PET视觉分析0.76,PET定量分析0.72,mpMRI 0.76,PET/CT联合mpMRI分析0.85。
- 68Ga-RM2摄取与Gleason评分不相关。
关键数值与推荐
- 免疫组化显示GRPR染色弱于PSMA,二者表达不相关(r=0.3882)。
临床怎么用
- 作者认为68Ga-RM2 PET/CT对原发前列腺癌检测和定位有前景,可补充mpMRI。
局限性
- 主要局限性是样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current imaging techniques may not detect all prostate cancer (PCa) lesions. OBJECTIVE: To evaluate positron emission tomography (PET)/computed tomography (CT) using the radiolabeled GRPR antagonist probe BAY86-7548 (68Ga-RM2) for localization of newly diagnosed PCa in comparison with multiparametric magnetic resonance imaging (mpMRI), histopathology, and immunohistochemistry (IHC). DESIGN, SETTING, AND PARTICIPANTS: This was a prospective study of 16 men with biopsy-proven PCa (2 low, 8 intermediate, and 6 high risk). 68Ga-RM2 PET/CT was performed within 4 wk after mpMRI and within 2 wk before radical prostatectomy and extended bilateral pelvic lymph node dissection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The presence of cancer was evaluated by blinded specialists using a 5-point Likert scale, with lesions scoring 4 or 5 considered positive, on 68Ga-RM2 PET/CT, mpMRI, and 68Ga-RM2 PET/CT-mpMRI fused images for each of 12 anatomic areas of the prostate. Whole-mount, step-section pathology served as the reference standard. Expression of GRPR and prostate-specific membrane antigen (PSMA) was analyzed via IHC of tumor paraffin sections. RESULTS AND LIMITATIONS: Of 192 areas analyzed, 128 contained cancer. The sensitivity, specificity, and accuracy of 68Ga-RM2 PET/CT imaging and mpMRI did not differ significantly; fusing the images maximized the sensitivity and accuracy (85.2% and 83.9%, respectively) and averaged the specificity (81.3%). The area under the receiver operating characteristic curve was 0.76 for PET visual analysis, 0.72 for PET quantitative analysis, 0.76 for mpMRI, and 0.85 for combined PET/CT and mpMRI analysis. 68Ga-RM2 uptake did not correlate with Gleason score. IHC analysis revealed weaker staining for GRPR than for PSMA, and the expression of these markers was not correlated (r=0.3882). The major limitation is the small sample size. CONCLUSIONS: 68Ga-RM2 PET/CT is promising for detection and localization of primary PCa, and complements mpMRI. GRPR expression appears to be independent from PSMA expression, suggesting that GRPR- and PSMA-targeted PET imaging may be complementary. PATIENT SUMMARY: This pilot prospective study shows that a positron emission tomography probe that binds to a marker of prostate cancer, GRPR, improves the ability of magnetic resonance imaging to detect prostate cancer.
引用
- Touijer KA, Michaud L, Alvarez HAV, et al. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31017093. doi:10.1016/j.euo.2018.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。